Resonant Capital Advisors LLC Has $260,000 Holdings in Novartis AG (NYSE:NVS)

Resonant Capital Advisors LLC boosted its stake in shares of Novartis AG (NYSE:NVS) by 6.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,676 shares of the company’s stock after purchasing an additional 162 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Novartis were worth $260,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Steigerwald Gordon & Koch Inc. grew its stake in shares of Novartis by 4.8% during the 3rd quarter. Steigerwald Gordon & Koch Inc. now owns 2,091 shares of the company’s stock worth $241,000 after acquiring an additional 95 shares in the last quarter. Centaurus Financial Inc. grew its stake in shares of Novartis by 1.7% during the 3rd quarter. Centaurus Financial Inc. now owns 5,728 shares of the company’s stock worth $659,000 after acquiring an additional 98 shares in the last quarter. FLC Capital Advisors grew its stake in shares of Novartis by 4.4% during the 3rd quarter. FLC Capital Advisors now owns 2,366 shares of the company’s stock worth $272,000 after acquiring an additional 100 shares in the last quarter. Clear Harbor Asset Management LLC grew its stake in shares of Novartis by 2.3% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 4,423 shares of the company’s stock worth $509,000 after acquiring an additional 100 shares in the last quarter. Finally, Allen Wealth Management LLC grew its stake in shares of Novartis by 1.8% during the 3rd quarter. Allen Wealth Management LLC now owns 5,788 shares of the company’s stock worth $666,000 after acquiring an additional 100 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently weighed in on NVS shares. BMO Capital Markets raised their price target on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research note on Wednesday, October 30th. Erste Group Bank reaffirmed a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. HSBC cut shares of Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Finally, StockNews.com cut shares of Novartis from a “strong-buy” rating to a “buy” rating in a research note on Friday. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $123.38.

Novartis Trading Up 0.8 %

NVS stock opened at $105.54 on Tuesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.11 and a quick ratio of 0.90. The company has a fifty day moving average price of $100.10 and a two-hundred day moving average price of $108.43. Novartis AG has a one year low of $92.35 and a one year high of $120.92. The stock has a market cap of $215.72 billion, a price-to-earnings ratio of 17.95, a price-to-earnings-growth ratio of 1.51 and a beta of 0.58.

Novartis (NYSE:NVS) last posted its earnings results on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, topping analysts’ consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.79% and a net margin of 23.56%. Equities analysts anticipate that Novartis AG will post 8.34 EPS for the current year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.